Anticancer drug-induced nephrotoxicity;Toxicité rénale des anticancéreux

Nephrologie et Therapeutique

Volumn 1, Issue 2, 2005, Pages 101-114

  Isnard Bagnis, Corinne ^a   Moulin, Bruno ^b   Launay Vacher, Vincent ^a   Izzedine, Hassan ^a   Tostivint, Isabelle ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL CIVIL   (France)

Author keywords

Carboplatin; Chronic renal failure; Cisplatine; Drug induced renal toxicity; Gemcitabine; H molytic uremic syndrome; Ifosfamide; Interf ron, M thotrexate; Tubular necrosis

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER PALLIATIVE THERAPY; CANCER RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; DRUG TOLERABILITY; HUMAN; KIDNEY FUNCTION; KIDNEY MALFORMATION; KIDNEY TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; REVIEW; TREATMENT OUTCOME;

EID: 23244450456     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2004.12.001     Document Type: Short Survey

References (102)

1. Launay-Vacher V, Izzedine H, Rey JB, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit 2004;10:CR209-CR212.
2. Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002;33: 121-6.
3. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
4. Berg KJ, Gjellestad A, Nordby G, et al. Renal effects of trimethoprim in ciclosporin- and azathioprine-treated kidney-allografted patients. Nephron 1989;53:218-22.
5. Hilbrands LB, Artz MA, Wetzels JF, Koene RA. Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int 1991;40:1171-6.
6. Saah AJ, Koch TR, Drusano GL. Cefoxitin falsely elevates creatinine levels. JAMA 1982;247:205-6.
7. Mitchell EK. Flucytosine and false elevation of serum creatinine level. Ann Intern Med 1984;101:278.
8. Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med 1980;93:280-1.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
10. Delanaye P, Chapelle JP, Gielen J, Krzesinski JM, Rorive G. Cystatin C in the evaluation of renal function. Nephrol 2003;24:457-68.
11. Reed CH. Diagnostic applications of cystatin C. Br J Biomed Sci 2000;57:323-9.
12. Harmoinen AP, Kouri TT, Wirta OR, et al. Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes. Clin Nephrol 1999;52:363-70.
13. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000;36:29-34.
14. Risch L, Blumberg A, Huber A. Rapid and accurate assessment of glomerular filtration rate in patients with renal transplants using serum cystatin C. Nephrol Dial Transplant 1999;14:1991-6.
15. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001; 37:79-83.
16. Stabuc B, Vrhovec L, Stabuc-Silih M, Cizej TE. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 2000;46:193-7.
17. Meijer S, Mulder N, Sleijfer D, et al. Nephrotoxicity of cis-diamminedichloride platinum [CDDP] during remission-induction and maintenance chemotherapy of the testicular carcinoma. Cancer Chemother Pharmacol 1982;8:27-30.
18. Brock P, Koliouska D, Baratt T, Yeomans E, Pritchard J. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 1991;118:531-4.
19. Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity. Am J Kidney Dis 1986;8:356-67.
20. Schilsky R, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cis-diamminedichloroplatinum II. Ann Intern Med 1979;90:929-31.
21. Seguro A, Shimizu M, Kudo L, dos Santos Rocha A. Renal concentration defect induced by cisplatin. The role of thick ascending limb and papillary collecting duct. Am J Nephrol 1989;9:59-65.
22. Kim S, Lee J, Nah M, et al. Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol 2001;12:875-82.
23. Bagnis C, Beaufils H, Jacquiaud C, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 2001;16:932-8.
24. Brillet G, Deray G, Lucsko M, et al. Definitive end-stage chronic kidney failure after cisplatin treatment. Nephrol 1993;14:227-9.
25. Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity insights into mechanism. Int J Androl 1987;10:325-46.
26. Tsuruya K, Ninomiya T, Tokumoto M, et al. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 2003; 63:72-82.
27. Megyesi J, Safirstein R, Price P. Induction of p21 in the kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 1998;101:777.
28. Ramesh G, Reeves W. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835-42.
29. Litterst C, Torres I, Guarino A. Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intravenous administration of cis-DDP [II]. J Clin Hemat Oncol 1977;7:169-78.
30. Safirstein R, Daye M, Miller P, Guttenplan J. Renal disposition and metabolism of liganded platinum: implications to toxicity. Fed Proc 1980;40:651A.
31. Safirstein R, Miller P, Guttenplan J. Uptake and metabolism of cisplatin by rat kidney. Kidney Int 1984;25:753-8.
32. e Édition. In: Guide de prescription des médicaments chez le patient insuffisant rénal. Méditions International P, ed; 2003.
33. Gorodetsky R, Vexler A, Bar-Khaim Y, Biran H. Plasma platinum elimination in a hemodialysis patient treated with cisplatin. Ther Drug Monit 1995;17:203-6.
34. Ozols R, Corden B, Jacob J, Wesley M, Ostchega Y, Young R. High-dose cisplatin in hypertonic saline. Ann Intern Med 1984;100:19-24.
35. Castiglione F, Dalla Mola A, Porcile G. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine. Tumori 1999;85:85-91.
36. Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol 1999;26:72-81.
37. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-12.
38. Schuchter L, Hensley M, Meropol N, Winer E. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice. Guidelines of the american society of clinical oncology. J Clin Oncol 2002;20:2895-903.
39. Howell S, Pfeifle C, Wung W, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845-51.
40. Martinez F, Deray G, Dubois M, et al. Comparative nephrotoxicity of carboplatin and cisplatin in euvolemic and dehydrated rats. Anticancer Drugs 1993;4:85-90.
41. Siddik Z, Jones M, Boxall F, Harrap K. Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 1988;21:19-24.
42. Reed E, Jacob J. Carboplatin and renal dysfunction. Ann Intern Med 1989;110:409.
43. Beyer J, Rick O, Weinknecht S, Kingreen D, Lenz K, Siegert W. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Bone Marrow Transplant 1997;20:813-9.
44. Calvert A, Newell D, Gumbrell L, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
45. Watanabe M, Aoki Y, Tomita M, et al. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol 2002;84:335-8.
46. Alberts DS, Dorr RT. New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors. Oncologist 1998;3:15-34.
47. Skinner R, Sharkey I, Pearson A. Ifosfamide, Mesna and nephrotoxicity in children. J Clin Oncol 1993;11:173-90.
48. Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F. Long term follow up of Ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an international society of pediatric oncology report. J Clin Oncol 1991;9:2177-82.
49. Stuart-Harris R, Harper P, Parson C. High-dose alkylation therapy using Ifosfamide infusion with Mesna in the treatment of adult soft-tissue sarcoma. Cancer Chemother Pharmacol 1983;11:69-74.
50. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis 2003; 41:292-309.
51. Rozenberg S, Lotze M. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukine 2 or high dose interleukine 2 alone. N Engl J Med 1987;316:889-97.
52. Rechner I, Brito-Babapulle F, Fielden J. Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF). Hematol J 2003;4:54-6.
53. de Azevedo AM, Goldberg Tabak D. Life-threatening capillary leak syndrome after G-CSF mobilization and collection of peripheral blood progenitor cells for allogeneic transplantation. Bone Marrow Transplant 2001;28:311-2.
54. Pulkkanen K, Kataja V, Johansson R. Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report. J Chemother 2003;15: 287-9.
55. De Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F. Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 2001;12:1651-2.
56. Yamamoto K, Mizuno M, Tsuji T, Amano T. Capillary leak syndrome after interferon treatment for chronic hepatitis C. Arch Intern Med 2002;162:481-2.
57. Zuber J, Martinez F, Droz D, Oksenhendler E, Legendre C. Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore) 2002;81:321-31.
58. Rosenstein M, Ettinghausen S, Rosenberg S. Extravasation of intravascular fluid wediated by the systemic administration of recombinant interleukin-2. J Immunol 1986;137: 1735-42.
59. Mercatello A, Hadj-Aissa A, Negrier S, et al. Acute renal failure with preserved renal plasma flow induced by cancer immunotherapy. Kidney Int 1991;40:309-14.
60. Guleria AS, Yang JC, Topalian SL, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 1994;12:2714-22.
61. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Huntingt) 2002;16:11-20.
62. Quan Jr. W, Brick W, Vinogradov M, Taylor WC, Khan N, Burgess R. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma. Cancer Biother Radiopharm 2004;19:350-4.
63. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998;83:797-805.
64. Mavroukakis SA, Muehlbauer PM, White Jr. RL, Schwartzentruber DJ. Clinical pathways for managing patients receiving interleukin 2. Clin J Oncol Nurs 2001;5:207-17.
65. Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001;24: 287-93.
66. Quesada J, Talpaz M, Rios A, Kurzrock R, Gutterman J. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234-43.
67. Yamamoto K, Mizuno M, Tsuji T, Amano T. Capillary leak syndrome after interferon treatment for chronic hepatatis C. Arch Intern Med 2002;162:481-2.
68. Aapro M, Martin C, Hatty S. Gemcitabine-a safety review. Anticancer Drugs 1998;9:191-201.
69. Fung M, Storniolo A, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999;85:2023-33.
70. van Hazel GA, Scott M, Rubin J, et al. Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination. Cancer Treat Rep 1983;67:805-10.
71. Schilcher RB, Young JD, Ratanatharathorn V, Karanes C, Baker LH. Clinical pharmacokinetics of high-dose mitomycin C. Cancer Chemother Pharmacol 1984;13:186-90.
72. Erlichman C, Rauth AM, Battistella R, Fine S. Mitomycin C pharmacokinetics in patients with recurrent or metastatic colorectal carcinoma. Can J Physiol Pharmacol 1987;65: 407-11.
73. Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989;7: 781-9.
74. Cantrell Jr. JE, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 1985;3:723-34.
75. Hanna WT, Krauss S, Regester RF, Murphy WM. Renal disease after mitomycin C therapy. Cancer 1981;48: 2583-8.
76. Gulati SC, Sordillo P, Kempin S, et al. Microangiopathic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil. Cancer 1980;45: 2252-7.
77. Bayle F, Vialtel P, Bastrenta F, et al. Thrombotic microangiopathy and chronic renal failure caused by mitomycin C in 4 women treated for breast cancer. Nouv Presse Med 1982;11:2300-1.
78. Liu K, Mittelman A, Sproul EE, Elias EG. Renal toxicity in man treated with mitomycin C. Cancer 1971;28:1314-20.
79. Lyman NW, Michaelson R, Viscuso RL, Winn R, Mulgaonakar S, Jacobs MG. Mitomycin-induced hemolytic-uremic syndrome. Successful treatment with corticosteroids and intense plasma exchange. Arch Intern Med 1983;143: 1617-8.
80. Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984;101:41-4.
81. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001;8:286-93.
82. Liegler DG, Henderson ES, Hahn MA, Oliverio VT. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 1969;10:849-57.
83. Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1978;3:1-13.
84. Breithaupt H, Kuenzlen E. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat Rep 1982;66:1733-41.
85. Jacobs SA, Stoller RG, Chabner BA, Johns DG. Dose-dependent metabolism of methotrexate in man and rhesus monkeys. Cancer Treat Rep 1977;61:651-6.
86. Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004;100:2222-32.
87. Pitman SW, Frei 3rd E. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep 1977;61:695-701.
88. Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986;1:256-8.
89. Kremer JM, Hamilton RA. The effects of nonsteroidal anti-inflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995; 22:2072-7.
90. Frei 3rd E, Jaffe N, Tattersall MH, Pitman S, Parker L. New approaches to cancer chemotherapy with methotrexate. N Engl JMed 1975;292:846-51.
91. Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983;1:208-16.
92. Molina R, Fabian C, Cowley Jr. B. Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency. Am J Med 1987;82:350-2.
93. Relling MV, Stapleton FB, Ochs J, et al. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer 1988;62:884-8.
94. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814.
95. Remuzzi G, Benigni A. Repairing renal lesions: will VEGF be the builder? Kidney Int 2000;58:2594-5.
96. Brown LF, Berse B, Tognazzi K, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992;42:1457-61.
97. Kretzler M, Schroppel B, Merkle M, et al. Detection of multiple vascular endothelial growth factor splice isoforms in single glomerular podocytes. Kidney Int Suppl 1998;67: S159-61.
98. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
99. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
100. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
101. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
102. Mavroukakis SA, Muehlbauer PM, White RL, Schwartzentruber DJ. Clinical pathways for managing patients receiving interleukin 2. Clin J Oncol Nurs 2001;5:207-17.